A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the filing for Q1 FY2025, filed May 15, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VINC SEC filings page.
This page shows Vincerx Pharma Inc (VINC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Financial Health Signals
We do not publish a peer-relative financial health score for Vincerx Pharma Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Vincerx Pharma Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Vincerx Pharma Inc reported a net loss of $30.1M while operations used $26.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Vincerx Pharma Inc's EBITDA was -$3.3M in Q1 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Vincerx Pharma Inc reported a net loss of $5.0M in Q1 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q1 2025.
Cash & Balance Sheet
Vincerx Pharma Inc held $4.4M in cash as of Q1 2025; no long-term debt figure is on record for that period.
Not reported for Q1 2025.
Not reported for Q1 2025.
Margins & Returns
Vincerx Pharma Inc's quarterly ROE was -242.0% in Q1 2025: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is up 51.5 percentage points.
Not reported for Q1 2025.
Not reported for Q1 2025.
Not reported for Q1 2025.
Capital Allocation
Vincerx Pharma Inc invested $1.0M in research and development in Q1 2025. This represents a decrease of 77.7% from the same quarter a year earlier. Against the prior quarter it is down 68.8%.
Not reported for Q1 2025.
Not reported for Q1 2025.
VINC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.0M-77.7% | $3.3M-12.0% | $3.9M-35.9% | $3.8M-54.5% | $4.6M-58.2% | $3.7M | $6.1M-44.9% | $8.2M-40.0% |
| SG&A Expenses | $2.3M-20.7% | $5.6M+205.4% | $3.9M+10.7% | $3.6M-5.2% | $2.9M-35.0% | $1.8M | $3.5M-22.5% | $3.8M-19.3% |
| Operating Income | -$3.3Mn/m | -$8.8Mn/m | -$7.8Mn/m | -$7.4Mn/m | -$7.5Mn/m | -$5.5M | -$9.6Mn/m | -$12.1Mn/m |
| EBITDA | -$3.3Mn/m | N/A | -$7.8Mn/m | -$7.4Mn/m | -$7.5Mn/m | N/A | -$9.6Mn/m | -$12.0Mn/m |
| Net Income | -$5.0Mn/m | -$8.0Mn/m | -$7.8Mn/m | -$1.8Mn/m | -$12.4Mn/m | -$5.0M | -$9.0Mn/m | -$11.6Mn/m |
| EPS (Basic) | -$1.40 | N/A | -$3.40 | -$1.00 | -$11.46 | -$4.60n/m | -$8.40 | -$10.80n/m |
| EPS (Diluted) | -$1.40 | N/A | -$15.85 | -$1.00 | -$11.46 | -$4.60n/m | -$37.72 | -$10.80n/m |
| Diluted Shares (Avg) | 4M | N/A | 2,284 | 2M | 1,085 | N/A | 1,067 | 1M+1.3% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
VINC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.7M-57.7% | $8.0M-56.1% | $14.9M-43.1% | $21.5M-39.0% | $11.1M-76.6% | $18.2M-69.3% | $26.3M-63.7% | $35.3M-59.8% |
| Current Assets | $4.7M-39.0% | $6.4M-56.5% | $11.7M-48.5% | $18.3M-42.5% | $7.7M-82.6% | $14.7M-73.7% | $22.8M-66.1% | $31.8M-61.4% |
| Cash & Equivalents | $4.4M-13.2% | $5.0M-61.0% | $2.9M-80.5% | $7.9M+18.6% | $5.1M+13.8% | $12.8M+9.6% | $15.1M-67.1% | $6.7M-91.7% |
| Short-Term Investments | $0n/m | $0n/m | $7.1M+24.8% | $8.4M-59.4% | $0-100.0% | $0-100.0% | $5.7M-71.6% | $20.7Mn/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $2.6M-77.6% | $5.3M-24.5% | $5.8M-44.6% | $6.1M-45.4% | $11.7M-9.8% | $7.0M-39.8% | $10.5M-16.8% | $11.1M-16.8% |
| Current Liabilities | $2.6M-75.4% | $5.3M-5.8% | $5.4M-38.7% | $5.3M-41.8% | $10.6M-0.7% | $5.6M-38.8% | $8.8M-11.1% | $9.2M-12.4% |
| Non-Current Liabilities | $0-100.0% | $0-100.0% | $415K-75.4% | $747K-62.3% | $1.1M-52.8% | $1.4M-43.5% | $1.7M-37.9% | $2.0M-32.4% |
| Total Equity | $2.1Mn/m | $2.7M-75.7% | $9.1M-42.1% | $15.4M-36.0% | -$622K-101.8% | $11.2M-76.5% | $15.7M-73.6% | $24.1M-67.5% |
| Retained Earnings | -$194.2Mn/m | -$189.2Mn/m | -$181.2Mn/m | -$173.3Mn/m | -$171.5Mn/m | -$159.1Mn/m | -$156.5Mn/m | -$146.8Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
VINC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.5Mn/m | -$6.2Mn/m | -$6.4Mn/m | -$5.8Mn/m | -$7.7Mn/m | -$8.0Mn/m | -$6.6Mn/m | -$12.7Mn/m |
| Depreciation & Amortization | $0-100.0% | $13K+8.3% | $13K-7.1% | $13K0.0% | $13K0.0% | $12K-14.3% | $14K+7.7% | $13K0.0% |
| Stock-Based Compensation | $435K-17.6% | N/A | $1.4M+126.2% | $912K-16.6% | $528K-61.8% | N/A | $629K-72.5% | $1.1M-67.5% |
| Investing Cash Flow | N/A | $7.2M+24.8% | $1.4M-90.9% | -$8.3M-156.3% | $0-100.0% | $5.8Mn/m | $15.1Mn/m | $14.8Mn/m |
| Financing Cash Flow | $3.9M+77020.0% | $985K+5372.2% | $0n/m | $17.0M+18181.7% | $5K+66.7% | $18K-52.6% | $0n/m | $93K-61.6% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
VINC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -242.0% | -293.5%-249.4pp | -86.1%-28.9pp | -11.7%+36.1pp | N/A | -44.1% | -57.2%-29.0pp | -47.9%-23.1pp |
| Return on Assets | -106.7%+5.4pp | -99.9%-72.7pp | -52.5%-18.2pp | -8.4%+24.3pp | -112.1%-81.3pp | -27.2% | -34.3%-11.0pp | -32.7%-11.8pp |
| Current Ratio | 1.79+1.1x | 1.21-1.4x | 2.17-0.4x | 3.430.0x | 0.72-3.4x | 2.63-3.5x | 2.58-4.2x | 3.47-4.4x |
| Liabilities-to-Equity | 1.27 | 1.94+1.3x | 0.640.0x | 0.39-0.1x | N/A | 0.62+0.4x | 0.67+0.5x | 0.46+0.3x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Vincerx Pharma Inc VINC | FY2024 | N/A | -$30.1M | N/A | $79K | — |
| Sigyn Therapeutics Inc SIGY | FY2024 | N/A | N/A | N/A | $145K | — |
| CERo Terapeutics Holding Inc CERO | FY2025 | N/A | N/A | N/A | $217K | — |
| Regen BioPharma Inc RGBP | FY2025 | $237K | -$1.3M | N/A | $355K | — |
| Carisma Therapeutics Inc CARM | FY2024 | $19.6M | -$60.5M | N/A | $8K | — |
| Lyra Therapeutics Inc LYRA | FY2025 | $398K | -$28.9M | N/A | $337K | — |
Where Vincerx Pharma Inc Ranks
Frequently Asked Questions
No, Vincerx Pharma Inc (VINC) reported a net loss of $22.6M over the trailing 12 months to March 31, 2025. In fiscal year 2024 it reported a net loss of $30.1M.
Vincerx Pharma Inc (VINC) had EBITDA of -$31.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
Vincerx Pharma Inc (VINC) has a return on equity of -1104.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
Vincerx Pharma Inc (VINC) recorded an outflow of $26.1M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
Vincerx Pharma Inc (VINC) had $8.0M in total assets as of fiscal year 2024, including both current and long-term assets.
Vincerx Pharma Inc (VINC) invested $15.5M in research and development during fiscal year 2024.
Vincerx Pharma Inc (VINC) had a current ratio of 1.21 as of fiscal year 2024, which is considered adequate.
Vincerx Pharma Inc (VINC) had a liabilities-to-equity ratio of 1.94 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2024, because the filing data we hold for that year carries no long-term debt figure.
Vincerx Pharma Inc (VINC) had a return on assets of -375.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Vincerx Pharma Inc (VINC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to March 31, 2025). The market capitalization is $79K as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Vincerx Pharma Inc (VINC) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $79K as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2024, Vincerx Pharma Inc (VINC) held $5.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $26.1M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Vincerx Pharma Inc (VINC) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Vincerx Pharma Inc (VINC) reported a net loss of $30.1M while operations used $26.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.